Education: MD, PhD
University of Colorado 1962
PHD University of Melbourne, Australia 1968
Dr. Robinson, a native of Colorado, earned his medical degree from University of Colorado Medical School. He completed an internship and residency at The Massachusetts General Hospital and then returned to the University of Colorado as the Chief Resident in Internal Medicine in 1965. He then did a PhD in Medical Biology and completed his fellowship at the The Walter and Eliza Hall Institute, University of Melbourne, Australia. He was one of the pioneers in the study of WBC regulation and was the first to describe and characterize human G-CSF. Dr. Robinson joined the faculty of University of Colorado Denver in 1968 and was the first head of the Division of Medical Oncology.
During his career, Dr. Robinson has received many teaching and research awards and has been honored numerous times for his contributions to medicine, specifically medical oncology. He has also spent time in India as a Fulbright Scholar training junior doctors and doing research.
Dr. Robinson is an active clinical and basic investigator studying the molecular and genetic regulation of melanocyte development and melanoma, particularly the role of microRNAs in the regulation of melanoma associated genes. Together with Dr Lynn Bemis he is investigating the use of nano-technology to detect mutations in cancer cells. He is the founder of the melanoma tissue bank at CU which provides research materials to local investigators and numerous national and international collaborators. He coordinates the Frontiers in Melanoma Seminar Program which brings in invited speakers from around the world for collaboration and discussion. In conjunction with the Dept of Dermatology he also has a major research effort in the genetics, molecular biology and development of giant congenital nevi.
Lewis KD, Robinson WA, McCarter M, Pearlman N, O’Day S, Anderson C, Gonzales R. Phase II Study of Neoadjuvant Biochemotherapy for Stage III Malignant Melanoma. J Clin Oncol 24:3157-63, 2006.
Ravdel L, Robinson WA, Lewis K, Gonzalez R. Metastatic melanoma in the breast: a report of 27 cases.J Surg Oncol. 94:101-4. 2006
Pearlman N, McCarter MD, Frank M, Hurtubis C, Merkow RP, Franklin WA, Gonzalez R, Lewis K, Roaten JB, Robinson WA. Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma. Am J Surg. 192:878-81. 2006
Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, et al Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res.12:1137-43. 2006
Escodar GA, Robinson WA, Nydam, TL et al Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation BMC Cancer 7:7-13 2007
Swick BL, Ravdel L, Fitzpatrick JE, Robinson WA, Merkel cell carcinoma: Evaluation of KIT expression.J of Cutaneous Path 34:324-27. 2007
Rifkin Endowment: $87,500 per year – ongoing
National Science Foundation. Nanoparticle detection of gene mutation. With Lynne Bemis. $1.1 million 9-1-06 – 8-31-09
Moore Family Foundation: $75,000 year: Melanoma Tissue Bank
SourceMD. Gene expression if peripheral blood of high risk melanoma patients $75,000/year 1-1-08 – 12-31-10